Minimal residual disease in multiple myeloma: why, when, where
WEBDec 10, 2021 · Understand the role of MRD status in prognosis in multiple myeloma. Explore how to apply MRD testing in clinical practice and its limitations. CLINICAL CASE.
MRD in multiple myeloma: does CR really matter?
WEBDec 8, 2022 · Multiple myeloma embodies the paradigm of the deeper the response, the longer the survival. However, results are conflicting regarding achievement of complete remission (CR) and minimal residual disease (MRD) negativity; some patients with persistent M protein have undetectable MRD.
Minimal residual disease in multiple myeloma: current status
WEBOct 14, 2021 · Multiple myeloma (MM) is a treatable plasma cell cancer with no cure. Clinical evidence shows that the status of minimal residual disease (MRD) after treatment is an independent prognostic factor of MM. MRD indicates the …
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone …
WEBDec 12, 2023 · Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and...
Measurable residual disease (MRD) dynamics in multiple myeloma …
WEBAug 7, 2024 · Minimal residual disease (MRD) assessment is a known surrogate marker for survival in multiple myeloma (MM) and sustained MRD has become the new therapeutic objective for MM treatment [1, 2].
Minimal Residual Disease in Multiple Myeloma: Current …
WEBMay 27, 2020 · The presence of Minimal Residual Disease (MRD), i.e., minute numbers of myeloma cells that may remain in the bone marrow (BM) of the patient after treatment, has been proved crucial for monitoring remission status and is …
Minimal Residual Disease Assessment in Multiple Myeloma …
WEBJan 26, 2022 · As a result, standardized and accessible MRD assessment across the disease spectrum of Myeloma (newly diagnosed to heavily pre-treated disease) could become a useful tool in drug development and clinical management of patients.
WEBApr 12, 2024 · MRD is a measure of the number of multiple myeloma cells in the patient’s bone marrow, and it is often used in patients with complete response (CR) to further quantify depth of...
What is minimal residual disease (MRD)? - MD Anderson Cancer Center
WEBJul 15, 2020 · Minimal residual disease (MRD) is common in patients with blood cancers, such as leukemia, lymphoma and multiple myeloma. But what does this mean for patients and their need for additional cancer treatment? Ghayas Issa, M.D., explains.
Minimal Residual Disease in Myeloma: Application for Clinical …
WEBOct 1, 2021 · The development of novel agents has transformed the treatment paradigm for multiple myeloma, with minimal residual disease (MRD) negativity now achievable across the entire disease spectrum. Bone marrow-based technologies to assess MRD, including approaches using next-generation flow and next-genera ….